Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
65.24 USD | +1.94% |
|
+7.06% | +3.55% |
07-16 | JPMorgan Adjusts Price Target on Incyte to $59 From $60, Maintains Neutral Rating | MT |
07-16 | Goldman Sachs Adjusts Price Target on Incyte to $61 From $60, Maintains Neutral Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.55% | 14.39B | |
+7.46% | 100B | |
+11.97% | 42.34B | |
-11.41% | 32.76B | |
+79.34% | 29.46B | |
-12.28% | 16.31B | |
-1.90% | 12.23B | |
+178.17% | 10.47B | |
+1.80% | 8.97B | |
-54.74% | 8.84B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Transcript : Incyte Corporation Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 07